Archive for the ‘Penny Stocks’ Category

« Older Entries
Newer Entries »

Notable Nasdaq Gainers – BSDM, LOJN, SIMG, RFMD

Wednesday, October 27th, 2010

Shares of BSD Medical Corporation (Nasdaq: BSDM) were up as much as 25 percent from Tuesday’s closing price of $3.94 per share, on Wednesday. Shares traded as high as $4.95 per share with nearly double the company’s average three-month volume. BSD Medical won the Frost & Sullivan “Technology Innovation of the Year Award” in 2005 for its BSD-2000 system. But its biggest money generator is the MicroThermX. BSDM’s patented “phased-array” technology generates heat allows doctors to kill massive clusters of cancer cells. Shares BSDM are up roughly 280 percent since the FDA granted the company clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue in August of this year.

Shares of JoJack Corp. (Nasdaq: LOJN) were up more than 34 percent from Tuesday’s closing price, in morning trading on Wednesday on nearly 7x the company’s average three month volume. The car recovery technology developer recently reported a 47 percent increase in third quarter international sales. The company also reported net income of $2.7 million, or 15 cents per share, up from a loss of $13.4 million, or 78 cents per share a year earlier. Consolidated third quarter revenue climbed 7 percent to $38.5 million, from a year ago. Shares of LOJN are up about 47 percent over the past three months.

Shares of chip maker, Silicon Image, Inc. (Nasdaq: SIMG) were up as much as 44 percent from Tuesday’s closing price, in morning trading on Wednesday. Shares traded as high as $6.57, up from Tuesday’s closing price of $4.55. Silicon Image earned $9.5 million, or 12 cents per share, compared to a net loss of $15.5 million, or 21 cents per share a year ago. Excluding items, the company earned 18 cents per share. Third quarter revenue increased 63 percent to $60.5 million, which included a $7.5 million royalty revenue catch-up. Analysts on average, expected the company to post earnings of a nickel per share (excluding items), on revenue of $49 million. The company sees fourth quarter revenue in the range of $46 million to $48 million, above analysts’ estimates of $45.4 million.

RF Micro Devices, Inc. (Nasdaq: RFMD) was up 13 percent from Tuesday’s closing price, in morning trading on Wednesday after the company posted revenue of $285.8 million, and EPS of 19 cents for its fiscal second quarter ended October 2. Analysts on average expected EPS of 16 cents, on revenue of $275.9 million. “On the strength of new product launches and diversification efforts, we continue to reduce our exposure at our largest customer while sales to all other customers grew year-over-year by approximately 53%,” said RFMD’s CEO Bob Bruggeworth in a conference call. “s a result, RFMD delivered our sixth consecutive quarter of expanding operating income with the September quarter representing another company record.” Shares of RFMD are up as much as 61 percent over the past three months.

Tags: , , , , , , , ,
Posted in Consumer Discretionary Stocks, Health Care Stocks, Penny Stocks, Technology Stocks | No Comments »

PharmAthene, Inc. (PIP) – Buzz Stock of the Day

Monday, October 18th, 2010

Shares of biodefense company PharmAthene, Inc. (AMEX: PIP) soared almost 32 percent from Friday’s closing price, in morning trading on Monday after WBB Securities upgraded its rating on the stock to a Strong Buy. The tailwind for PharmAthene began last week after it was announced that the  NYSE Amex LLC (NYSE Amex) determined that the Company made a reasonable demonstration of its ability to regain compliance with the  NYSE Amex listing requirements and granted PharmAthene an extension until January 26, 2012 to demonstrate its compliance.

PharmAthene also caught a huge boost from last week’s news that the United States is spending up to $2.8 billion to shore up its defenses against biological warfare, according to SIGA Technologies, Inc. (Nasdaq: SIGA), the drugmaker who expects to get a government contract to supply smallpox antiviral drugs.In December 2006, PharmAthene had filed a case against SIGA pursuant to a merger agreement between the companies that was terminated in October 2006. The trial is expected to start on Jan. 3, 2011. Noble Financial Capital Markets analyst Raghuram Selvaraju expects the court case with PharmAthene to be ruled in its favor, with PharmAthene getting a percentage of SIGA’s contract with the government. Roth Capital Partners analyst Joseph Pantginis said the contract has positive implications to PharmAthene that can now identify the exact measure of potential damages.
[–quote–]
TheStreet.com’s James Altucher recently wrote that on the basis of this contract alone, Pharmathene would potentially make up to a billion dollars in cash earnings. “On this one catalyst I think PIP is potentially a $7 – $12 stock,” he stated in his October 15, 2010 article.

PharmAthene is also positioning its anthrax vaccine, Valortim, as a potential alternative to the existing vaccine that is administered to military personnel and individuals who work in high-risk environments. Anthrax is considered the Department of Defense’s No. 1 biological threat.  The US is required to have a stockpile of 75 million doses of vaccine. Right now, the only approved supplier of doses of vaccine is EBS, which has a long-approved first-generation vaccine that requires 5 doses over 18 months and costs $120 per dose. PIP’s second-generation vaccine requires 3 doses over 60 days and costs about $45 a dose, according to PharmAthene’s Chief Executive Officer, Eric Richman.

Tags: , , , , , , ,
Posted in Health Care Stocks, Penny Stocks | No Comments »

EntreMed, Inc. (ENMD) – Buzz Stock of the Day

Thursday, August 19th, 2010

Shares of oncology-focused drug developer, EntreMed, Inc. (Nasdaq: ENMD) were up as much as 28 percent from Wednesday’s closing price in morning trading on Thursday. The company recently announced a second quarter net loss of $4.9 million, or 62 cents per share, compared with a net loss of $3.1 million, or 46 cents per share for the same period a year ago.

According to EntreMed’s Executive Chairman, Michael Tarnow, the second quarter was “pivotal” for the company. “During the second quarter, we achieved a critical milestone with the initiation of a multi-center Phase 2 study for ENMD-2076 in ovarian cancer patients,” he said in a statement.
[–quote–]
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.

Last month, the company announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma (MM) cell lines and in MM models in vivo. Results of the study, conducted by EntreMed’s collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University School of Medicine, were published in the on-line version of the British Journal of Haematology on June 15, 2010 and were scheduled to be published in print in the August 1.

For the first six months of 2010 the reported net loss was ($7.1 million), or ($0.95) per share as compared to ($6.6 million), or ($0.98) per share for 2009.

As of June 30, 2010, EntreMed had cash and short-term investments of approximately $8 million.

EntreMed announced a 1-for-11 reverse stock split on June 30, 2010, to better enable the company to maintain its listing on the Nasdaq Capital Market. As a result of the reverse split, the number of shares of outstanding common stock will be approximately 9.5 million, excluding stock options and unexercised warrants and subject to adjustment for fractional shares.

Tags: , , , , ,
Posted in Health Care Stocks, Penny Stocks | No Comments »

Pacific Ethanol, Inc. (PEIX) – Buzz Stock of the Day

Tuesday, August 17th, 2010

We first covered Pacific Ethanol, Inc. (Nasdaq: PEIX) on June 30, 2010, after the company announced that four of its wholly-owned subsidiaries had emerged from bankruptcy. Shares were up almost 60 percent on that day, from the previous day’s closing price.

Shares of Pacific Ethanol surged again on Tuesday, this time as much as 42 percent from the previous day’s closing price after the company posted earnings of $107.8 million or $1.43 per share for the three months ended June 30, compared to a loss of $28.2 million or 49 cents per share in the same period last year. The boost in earnings was primarily due a non-cash gain of $119 million, and an 88 percent increase in total gallons sold, offset by a  lower average price per gallon.
[–quote–]
Net sales in the quarter increased 9 percent to $76.8 million, compared to $70.1 million in the same quarter a year ago. The company also reduced its SG&A expenses by 49 percent, and improved adjusted EBITDA by $8.4 million, compared to the second quarter of 2009.

Pacific Ethanol’s CEO Neil Koehler described the second quarter as “pivotal” for the company. “We delivered sales growth, dramatically reduced operating expenses, and improved adjusted EBITDA,” he said in a statement. “We successfully led the production facilities out of bankruptcy effective June 29th, substantially reducing our debt and other liabilities by $295 million. During the quarter, we also reduced other debt by $9 million. In addition to strengthening our balance sheet, we reduced selling, general and administrative expenses to less than half of what they were for the same quarter last year, thus establishing a stable platform for growth.”

On June 29, 2010, PEI’s wholly-owned plant holding company, PEH, and its four plant subsidiaries exited bankruptcy and the ownership of PEH was transferred to certain lenders. As a result, PEI recorded a $119.4 million non-cash gain from the disposition of liabilities of $294.5 million net of assets of $175.1 million that were removed from its balance sheet. Simultaneously, PEI began operating under its newly announced operating and marketing agreements with the ethanol production facilities upon their emergence from bankruptcy.

Tags: , , , ,
Posted in Energy Stocks, Industrial Stocks, Penny Stocks | No Comments »

Alphatrade.com (APTD) – Micro-Cap Buzz Stock

Tuesday, August 10th, 2010

Shares of Alphatrade.com (OTCBB: APTD) were up more than 60 percent from Monday’s closing price in afternoon trading on Tuesday. Over the past few weeks, Alphatrade has been featured in several penny stock newsletters, most of which have touted the company as “setting itself up for what looks like a major breakout.”

Most recently, Alphatrade issued a press release announcing that the company was “pleased” with its cash flow positive position.
[–quote–]
“Our growth can be described as proficient, we offer cost effective solutions to both corporate and retail users. In addition, it is our goal in these tough economic times, to offer dollar-for-dollar the best product in the market.” stated CEO Gordon Muir in a statement.

Alphatrade’s revenues for the three months ended March 31, 2010 were $892,395,  49 percent lower than the $1,751,146 in revenue the company reported for the same period in 2009. The sharp drop was largely due to a 74 percent decline in advertising revenue, which shrunk to $263,001 in the quarter from $1,045,846 in the same period a year ago.

Despite the drop in revenue, Alphatrade managed to swing to a profit of  of $62,692 for the three months ended March 31, 2010 compared to a loss of ($310,179) for the three months ended March 31, 2009. The company also saw a 69 percent increase in revenue from sales of its E-Trax tool and web site development programs. Revenue from these products was $88,496 during the quarter ended March 31, 2010 compared to $52,442 for the same period in 2009.

According to a recent press release, Alphatrade.com is preparing to report “a positive 2nd Quarter cash flow subsequent to positive 1st Quarter cash flow reported earlier this year.”

AlphaTrade was incorporated in 1998 and currently has 16 employees committed to sales, marketing, customer service, programming, coding and general administration.

Tags: , , , ,
Posted in Penny Stocks, Technology Stocks | No Comments »

« Older Entries
Newer Entries »